Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| PRECIGEN, INC. | 1,243,239 | reported | 13 Mar 2026 | tx 49+2,397,551−438,679 |
| Bausch Health Companies Inc. | 53,969 | reported | 29 Aug 2013 | tx 2+53,969 |
| EyePoint, Inc. | 40,000 | reported | 02 Jan 2026 | tx 3+140,000 |
| BridgeBio Pharma, Inc. | 25,889 | reported | 20 Jun 2025 | tx 7+266,619 |
| Cocrystal Pharma, Inc. | 16,410 | reported | 09 Jan 2026 | tx 5+1,110,949 |
| AMGEN INC | 9,191 | reported | 05 May 2020 | tx 8+9,191 |
| AVON PRODUCTS INC | 5,476 | reported | 03 May 2012 | tx 13+46,484−16,000 |
| TIME WARNER INC | 0 | reported | 14 Jun 2018 | tx 48+95,497.34−96,711.34 |
| Merck & Co., Inc. | 0 | reported | 03 Nov 2009 | tx 58+7,964,707−8,994,561.57 |
| Prometheus Biosciences, Inc. | 0 | reported | 16 Jun 2023 | tx 8+63,677−63,677 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 13 Mar 2026 | EXERCISE | PRECIGEN, INC. | 71,839 | — | |
| 13 Mar 2026 | EXERCISE | PRECIGEN, INC. | 71,839 | 0.00 USD | deriv |
| 10 Mar 2026 | GRANT_AWARD | PRECIGEN, INC. | 17,948 | 3.51 USD | |
| 10 Mar 2026 | GRANT_AWARD | PRECIGEN, INC. | 41,073 | 0.00 USD | deriv |
| 10 Mar 2026 | GRANT_AWARD | PRECIGEN, INC. | 35,612 | 0.00 USD | deriv |
| 09 Jan 2026 | GRANT_AWARD | Cocrystal Pharma, Inc. | 16,410 | 0.00 USD | deriv |
| 02 Jan 2026 | GRANT_AWARD | EyePoint, Inc. | 40,000 | 0.00 USD | deriv |
| 28 Oct 2025 | GRANT_AWARD | Cocrystal Pharma, Inc. | 359,713 | 1.39 USD | |
| 28 Oct 2025 | GRANT_AWARD | Cocrystal Pharma, Inc. | 719,426 | 1.39 USD | deriv |
| 20 Jun 2025 | GRANT_AWARD | BridgeBio Pharma, Inc. | 6,589 | 0.00 USD | |
| 20 Jun 2025 | GRANT_AWARD | BridgeBio Pharma, Inc. | 8,425 | 0.00 USD | deriv |
| 14 Mar 2025 | EXERCISE | PRECIGEN, INC. | 87,412 | — | |
| 13 Mar 2025 | GRANT_AWARD | PRECIGEN, INC. | 36,206 | 1.74 USD | |
| 13 Mar 2025 | GRANT_AWARD | PRECIGEN, INC. | 83,517 | 0.00 USD | deriv |
| 13 Mar 2025 | GRANT_AWARD | PRECIGEN, INC. | 71,839 | 0.00 USD | deriv |
| 14 Mar 2025 | EXERCISE | PRECIGEN, INC. | 87,412 | 0.00 USD | deriv |
| 03 Jan 2025 | GRANT_AWARD | EyePoint, Inc. | 40,000 | 0.00 USD | deriv |
| 09 Oct 2024 | GRANT_AWARD | Cocrystal Pharma, Inc. | 8,067 | — | |
| 03 Sept 2024 | GRANT_AWARD | EyePoint, Inc. | 60,000 | 0.00 USD | deriv |
| 21 Jun 2024 | GRANT_AWARD | BridgeBio Pharma, Inc. | 26,014 | 0.00 USD | deriv |
| 14 Mar 2024 | GRANT_AWARD | PRECIGEN, INC. | 44,055 | 1.43 USD | |
| 14 Mar 2024 | GRANT_AWARD | PRECIGEN, INC. | 101,626 | 0.00 USD | deriv |
| 14 Mar 2024 | GRANT_AWARD | PRECIGEN, INC. | 87,412 | 0.00 USD | deriv |
| 09 Mar 2024 | EXERCISE | PRECIGEN, INC. | 106,837 | — | |
| 09 Mar 2024 | EXERCISE | PRECIGEN, INC. | 106,837 | 0.00 USD | deriv |
7 purchases reported after at least 12 months of silence — most recent on 14 Aug 2023.